Bicara Therapeutics to Present at the 2023 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., June 1, 2023 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to modulate the tumor microenvironment to elicit a potent and durable anti-tumor response, today announced that Claire Mazumdar, Ph.D., MBA, Chief Executive Officer, will present at the 2023 Jefferies Global Healthcare Conference in New York, NY on Thursday, June 8, 2023 at 11:00 am ET.

About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of well-validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara’s lead product candidate, BCA101, is a first-in-class EGFR / TGF-β-trap bifunctional antibody currently being evaluated in a Phase 1/1b study. For more information, please visit www.bicara.com or follow us on LinkedIn or Twitter.

Contacts:
Investors:
Sarah McCabe
Stern Investor Relations, Inc.
[email protected]

Media:
Dan Budwick
1AB
[email protected]